Merck and Bristol-Myers Squibb brace for loss of lucrative drug patents

New quarterly earnings reports offer insight into how the companies are preparing to potentially lose significant sources of revenue

Related Keywords

Bristol Myers Squibb ,Christophers Boerner ,Robertm Davis , ,Wall Street ,Harpoon Therapeutics ,Aqua Business ,Merck ,Bristol Myers ,Health ,Medical ,Dharma ,Winrevair ,Pembrolizumab ,Apixaban ,Keytruda ,Merck Amp Co ,Player ,Business ,Inance ,Orphan Drugs ,Antineoplastic Drugs ,Schering Plough ,Pharmaceutical Industry ,Ancer Immunotherapy ,Uartz ,